Skip to main content
Clinical Trials/NCT04997590
NCT04997590
Unknown
Not Applicable

Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in Promoting Traumatic Fracture Healing

Qianfoshan Hospital1 site in 1 country40 target enrollmentDecember 10, 2020

Overview

Phase
Not Applicable
Intervention
Umbilical cord blood mononuclear cells
Conditions
Bone Nonunion
Sponsor
Qianfoshan Hospital
Enrollment
40
Locations
1
Primary Endpoint
Bone defect connection
Last Updated
4 years ago

Overview

Brief Summary

The aim of this study is to explore the effectiveness and safety of umbilical cord blood mononuclear cells in promoting traumatic fracture healing.

Detailed Description

Umbilical cord blood mononuclear cells are a type of cell group containing hematopoietic stem cells, mesenchymal stem cells, neural stem cells, endothelial cells, immune cells, etc.In this study ,umbilical cord blood mononuclear cells will be used in promoting traumatic fracture healing,and the effectiveness and safety of the treatment plan was evaluated by twelve months of follow-up after treatment.

Registry
clinicaltrials.gov
Start Date
December 10, 2020
End Date
December 10, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Qianfoshan Hospital
Responsible Party
Principal Investigator
Principal Investigator

Lili Cao

Professor

Qianfoshan Hospital

Eligibility Criteria

Inclusion Criteria

  • Traumatic long bone fracture.
  • Noninfectious bone nonunion, delayed bone union.
  • 3 months after the operation of the fracture, the examination showed no callus growth, no signs of progressive repair at the fracture site, fracture piece space \< 5mm.
  • No shortening, angulation and displacement.
  • There was no obvious callus growth 8 months after local bone grafting.

Exclusion Criteria

  • There are infection foci at and near the fracture end after fracture.
  • 3 months after the fracture, tests showed partial callus growth.
  • Combining shortening, angulation and displacement phenomena.
  • Partial callus grew 8 months after local bone grafting.

Arms & Interventions

Umbilical cord blood mononuclear cells group

Umbilical cord blood mononuclear cells (cell number 1×108/2mL), once every two weeks, 3 times in total.

Intervention: Umbilical cord blood mononuclear cells

Staphylococcal Enterotoxin C group

Staphylococcal enterotoxin C (2mL), once every two weeks, 3 times in total.

Intervention: Staphylococcal Enterotoxin C

Outcomes

Primary Outcomes

Bone defect connection

Time Frame: 1 month to 1 year after treatment

0 points for complete fracture lines, 2 points for partial fracture lines, 4 points for lack of fracture lines.

Bone formation

Time Frame: 1 month to 1 year after treatment

If there is no bone formation, 0 points. Bone formation accounts for 25% of the fracture area, 1 point. Bone formation accounts for 50% of the fracture area, 2 points. Bone formation accounts for 75% of the fracture area, 3 points. Bone filled the gap between fracture ends, 4 points.

Bone reconstruction

Time Frame: 1 month to 1 year after treatment

0 points for no manifestations of reconstruction,2 points for intramedullary cavity can be reconstructed , and 4 points for the cortical bone can be completely reconstructed. A total score of 11 points or more achieves a good healing effect.

Study Sites (1)

Loading locations...

Similar Trials